Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury-Reference-Cited by-同舟云学术

Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury

Published:2017-06-28 Issue:7 Volume:13 Page:767-782
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Weaver Richard J.¹^ORCID,Betts Catherine²,Blomme Eric A.G.³,Gerets Helga H.J.⁴,Gjervig Jensen Klaus⁵,Hewitt Philip G.⁶,Juhila Satu⁷,Labbe Gilles⁸,Liguori Michael J.³,Mesens Natalie⁹,Ogese Monday O.²,Persson Mikael¹⁰,Snoeys Jan¹¹,Stevens James L.¹²,Walker Tracy¹³,Park B. Kevin¹⁴

Affiliation:

1. Research & Biopharmacy, Institut de Recherches Internationales Servier, Suresnes, France

2. Pathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge, UK

3. Preclinical Safety, AbbVie, North Chicago, USA

4. Non Clinical Development, Chemin du Foriest, UCB BioPharma SPRL, Braine L’Alleud, Belgium

5. Drug ADME Research, H. Lundbeck A/S, 9 Ottiliavej, Valby, Denmark

6. Non-Clinical Development, Merck KGaA, Darmstadt, Germany

7. In Vitro Biology, Orion Pharma, Espoo, Finland

8. Investigative Toxicology, Preclinical Safety, Sanofi R&D, Paris, France

9. Preclinical Development & Safety, Janssen (Pharmaceutical Companies of Johnson & Johnson) Turnhoutseweg 30, Beerse, Belgium

10. Innovative Medicines and Early Clinical Development, Drug Safety and Metabolism, Discovery Safety, AstraZeneca R&D, Mölndal, Sweden

11. Pharmacokinetics Dynamics & Metabolism, Janssen (Pharmaceutical Companies of Johnson & Johnson) Turnhoutseweg 30, Beerse, Belgium

12. Dept of Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA

13. Investigative Safety & Drug Metabolism, GlaxoSmithKline, David Jack Centre for Research and Development, Ware, Herts, Hertfordshire, UK

14. Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Funder

Innovative Medicines Initiative

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2017.1341489

Reference126 articles.

1. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals

2. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

3. Competency of different cell models to predict human hepatotoxic drugs

4. The application of engineered liver tissues for novel drug discovery

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability;Liver International;2024-01-13

2. <i>In Vitro</i> Assessment of Drug-Induced Liver Injury Using Cell-Based Models: A Review;Safety and Risk of Pharmacotherapy;2023-04-19

3. The evolving role of investigative toxicology in the pharmaceutical industry;Nature Reviews Drug Discovery;2023-02-13

4. Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism;Drug Metabolism Reviews;2022-01-02

5. Novel clinical biomarkers for drug-induced liver injury;Drug Metabolism and Disposition;2021-12-13